The Identification of Heavy Metal Accumulator Ferns in Abandoned Mines in the Philippines With Applications to Mine Rehabilitation and Metal Recovery

This paper focuses on the identification of some plant accumulators of heavy metals that can facilitate mine remediation and rehabilitation in the Philippines and metal recovery or phytomining. Most of these hyperaccumulators are ferns that thrive very well in different terrains and of particular interest are Pityrogramma calomelanos, Pteris vittata, and Pteris melanocaulon that are abundant in abandoned CueAu mining areas. The amounts of Cu and As in the soil and in the aboveground (AG) and belowground (BG) components of the accumulator ferns were determined and the Bioaccumulation Factor (BF) and the Translocation Factor (TF) were derived. Efforts to propagate the accumulator ferns identified from spores were successful, thus providing the opportunity of using them for various experiments on mine rehabilitation and metal recovery. The results of these experiments indicated that these hyperaccumulator ferns have the greatest potential for the remediation of metal contaminated soils, the rehabilitation of abandoned mines, and phytomining

New Evidence on Regucalcin, Body Composition, and Walking Ability Adaptations to Multicomponent Exercise Training in Functionally Limited and Frail Older Adults

Background: Regucalcin, or senescence marker protein-30 (SMP30), is a Ca2+-binding protein with multiple functions reported in the literature. Physical exercise has been shown to improve aging markers; nevertheless, SMP30 in humans has not been extensively researched. Older adults experience a decline in functional capacity and body composition. The purpose of this study was to examine the effects of a multicomponent training (MCT) program on SMP30 and its regulation of walking ability and body composition in functionally limited, frail, and pre-frail older adults. Methods: A total of 34 older adults (aged 80.3 +/- 6.1 years) were divided into an intervention group (IG = 20) and control group (CG = 14). The IG performed a supervised MCT (strength, endurance, balance, coordination, and flexibility) program for 6 months, 3 days per week, whereas the CG continued their normal lives without any specific physical training. SMP30 was analyzed in plasma after 3 and 6 months of MCT, while some physical fitness variables (Timed Up and Go (TUG) and 6-min walk test (6MWT)) and body composition (fat mass and lean mass) were measured at baseline, as well as after 3 months and 6 months of MCT. Results: No significant changes were observed in SPM30 between the IG (877.5 a.u. to 940.5 a.u., respectively) and CG (790.4 a.u. to 763.8 a.u., respectively). Moreover, no SMP30 differences were found between groups after 3 and 6 months of MCT. The IG improved significantly in the 6MWT after 3 months (472.2 +/- 84.2 m) compared to baseline (411.2 +/- 75.2 m). The IG also significantly enhanced their TUG performance after 3 months (7.6 +/- 1.6 s) and 6 months (7.3 +/- 1.8 s) of training compared to baseline (9.3 +/- 3.2 s) (all, p < 0.001). There were no significant differences in body composition between the IG and CG through the 6 months of MCT. Conclusions: The present study suggests that MCT did not change SMP30 levels from 3 to 6 months, where there were changes in neither walking ability nor body composition; however, MCT was effective in improving 6MWT and TUG performance from baseline to 3 months

Targeted glutamate supply boosts insulin concentrations, ovarian activity, and ovulation rate in yearling goats during the anestrous season

The neuroendocrine regulation of the seasonal reproductive axis requires the integration of internal and external signals to ensure synchronized physiological and behavioral responses. Seasonal reproductive changes contribute to intermittent production, which poses challenges for optimizing goat product yields. Consequently, a significant objective in seasonal reproduction research is to attain continuous reproduction and enhance profitability in goat farming. Glutamate plays a crucial role as a modulator in several reproductive and metabolic processes. Hence, the aim of this study was to evaluate the potential impact of exogenous glutamate administration on serum insulin concentration and ovarian function during the out-of-season period in yearling goats. During the anestrous season, animals were randomly located in individual pens to form two experimental groups: (1) glutamate (n = 10, live weight (LW) = 29.1 ± 1.02 kg, body condition score (BCS) = 3.4 ± 0.2 units) and (2) control (n = 10; LW = 29.2 ± 1.07 kg, BCS = 3.5 ± 0.2), with no differences (p < 0.05) regarding LW and BCS. Then, goats were estrus-synchronized, and blood sampling was carried out for insulin quantification. Ovaries were ultrasonographically scanned to assess ovulation rate (OR), number of antral follicles (AFs), and total ovarian activity (TOA = OR + AF). The research outcomes support our working hypothesis. Certainly, our study confirms that those yearling goats treated with exogenous glutamate displayed the largest (p < 0.05) insulin concentrations across time as well as an augmented (p < 0.05) out-of-season ovarian activity

First month prednisone dose predicts prednisone burden during the following 11 months: An observational study from the RELES cohort

Aim: To study the influence of prednisone dose during the first month after systemic lupus erythematosus (SLE) diagnosis (prednisone-1) on glucocorticoid burden during the subsequent 11 months (prednisone-2–12). Methods: 223 patients from the Registro Español de Lupus Eritematoso Sistémico inception cohort were studied. The cumulative dose of prednisone-1 and prednisone-2–12 were calculated and recoded into a four-level categorical variable: no prednisone, low dose (up to 7.5 mg/day), medium dose (up to 30 mg/day) and high dose (over 30 mg/day). The association between the cumulative prednisone-1 and prednisone-2–12 doses was tested. We analysed whether the four-level prednisone-1 categorical variable was an independent predictor of an average dose >7.5 mg/day of prednisone-2–12. Adjusting variables included age, immunosuppressives, antimalarials, methyl-prednisolone pulses, lupus nephritis and baseline SLE Disease Activity Index (SLEDAI). Results: Within the first month, 113 patients (51%) did not receive any prednisone, 24 patients (11%) received average low doses, 46 patients (21%) received medium doses and 40 patients (18%) received high doses. There was a strong association between prednisone-1 and prednisone-2–12 dose categories (p7.5 mg/day, while patients receiving low-dose prednisone-1 were not (adjusted OR 1.4, 95% CI 0. 0.38 to 5.2). If the analysis was restricted to the 158 patients with a baseline SLEDAI of =6, the model did not change. Conclusion: The dose of prednisone during the first month after the diagnosis of SLE is an independent predictor of prednisone burden during the following 11 months

Lead Optimization of 3,5-Disubstituted-7-Azaindoles for the Treatment of Human African Trypanosomiasis

Neglected tropical diseases such as human African trypanosomiasis (HAT) are prevalent primarily in tropical climates and among populations living in poverty. Historically, the lack of economic incentive to develop new treatments for these diseases has meant that existing therapeutics have serious shortcomings in terms of safety, efficacy, and administration, and better therapeutics are needed. We now report a series of 3,5-disubstituted-7-azaindoles identified as growth inhibitors of Trypanosoma brucei, the parasite that causes HAT, through a high-throughput screen. We describe the hit-to-lead optimization of this series and the development and preclinical investigation of 29d, a potent antitrypanosomal compound with promising pharmacokinetic (PK) parameters. This compound was ultimately not progressed beyond in vivo PK studies due to its inability to penetrate the blood-brain barrier (BBB), critical for stage 2 HAT treatments

Testing of cryogenic photomultiplier tubes for the MicroBooNE experiment

The MicroBooNE detector, to be located on axis in the Booster Neutrino Beamline (BNB) at the Fermi National Accelerator Laboratory (Fermilab), consists of two main components: a large liquid argon time projection chamber (LArTPC), and a light collection system. Thirty-two 8-inch diameter Hamamatsu R5912-02mod cryogenic photomultiplier tubes (PMTs) will detect the scintillation light generated in the liquid argon (LAr). This article first describes the MicroBooNE PMT performance test procedures, including how the light collection system functions in the detector, and the design of the PMT base. The design of the cryogenic test stand is then discussed, and finally the results of the cryogenic tests are reported

The Vista Variables in the Via Lactea (VVV) ESO Public Survey: Current Status and First Results

25 pages, 18 figures. To appear in the Carnegie Observatories Astrophysics Series, Volume 525 pages, 18 figures. To appear in the Carnegie Observatories Astrophysics Series, Volume 5Vista Variables in the Via Lactea (VVV) is an ESO Public Survey that is performing a variability survey of the Galactic bulge and part of the inner disk using ESO's Visible and Infrared Survey Telescope for Astronomy (VISTA). The survey covers 520 deg^2 of sky area in the ZYJHK_S filters, for a total observing time of 1929 hours, including ~ 10^9 point sources and an estimated ~ 10^6 variable stars. Here we describe the current status of the VVV Survey, in addition to a variety of new results based on VVV data, including light curves for variable stars, newly discovered globular clusters, open clusters, and associations. A set of reddening-free indices based on the ZYJHK_S system is also introduced. Finally, we provide an overview of the VVV Templates Project, whose main goal is to derive well-defined light curve templates in the near-IR, for the automated classification of VVV light curves

The insecticides permethrin and chlorpyrifos show limited genotoxicity and no leukemogenic potential in human and murine hematopoietic stem progenitor cells

Altres ajuts: European Food and Safety Authority, EFSA.PRAS.2018.04-CT1; Consejo Nacional de Ciencia y Tecnología, CB-2012-01-183467; Centro de Investigación Biomédica en Red en Cáncer, PID2019-104695RBI00; Asociación Española Contra el Cáncer, AECC INVES211226MOLI